drugset

drugset / Trial / NCT07147946

Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

NCT07147946 ↗

Phase 3 Not yet recruiting 666 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)

Timeline

Start: 2025-09
Primary completion: 2027-03
Completion: 2027-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TQC3721	Unknown	6 mg	Inhaled

Indications